Please assess the completion status of the following clinical trial:

Trial Title: Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* At least eight (8) years of education~* Geriatric Depression Scale (GDS) (62) score \< 6~* Hachinski Ischemic Score ≤ 4~* Normal general cognitive function as well as 1) normal memory function, documented by MOCA score of 23 or greater, and a RBANS Delayed Memory Index score of 85 or greater.~Exclusion Criteria:~* Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of significant head trauma or known structural brain abnormalities~* Major psychiatric disease or chronic unstable medical conditions~* History of drug abuse~* History of alcohol abuse (4 or greater drinks per day on average)~* Unable to complete MRI scans (no Pacemaker/Defibrillator)~* Known clinically significant abnormalities in B12 or thyroid function tests~* End Stage Renal Disease (ESRD)~* Hemodialysis (HD)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- AGB101 220 mg, then Placebo (Type: EXPERIMENTAL): AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
- Placebo, then AGB101 220 mg (Type: EXPERIMENTAL): Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).